Stem cell culture conditions and stability:A joint workshop of the PluriMes Consortium and Pluripotent Stem Cell Platform
| Autor: | Amit Chandra, Venkat Pisupati, Lynn Csontos, Jason A. Halliwell, Glyn Stacey, Mark J.S. McCall, Zoe Hewitt, Malin Parmar, Giulio Cossu, M Beatrice Panico, Ravenska Wagey, Harry Moore, Oliver Thompson, Peter W. Andrews, Valentin P. Shichkin, Thomas J. R. Frith, Ivana Barbaric, Francesco Tedesco, Alison Stacey, Charlotta Böiers |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Pluripotent Stem Cells
Engineering Embryology 0206 medical engineering Cell Culture Techniques Cell- and Tissue-Based Therapy Biomedical Engineering regenerative medicine 02 engineering and technology Stem cell culture Regenerative medicine Article Cell therapy Scientific discourse 03 medical and health sciences cell-based medicines Humans Biomanufacturing Induced pluripotent stem cell 030304 developmental biology 0303 health sciences mesenchymal cells business.industry Mesenchymal stem cell Cell Differentiation clinical trial Congresses as Topic 020601 biomedical engineering 3. Good health Adult Stem Cells manufacturing Engineering ethics Stem cell cell therapy pluripotent stem cells business Adult stem cell characterization regulation |
| Zdroj: | Stacey, G N, Andrews, P W, Barbaric, I, Boiers, C, Chandra, A, Cossu, G, Csontos, L, Frith, T J, Halliwell, J A, Hewitt, Z, McCall, M, Moore, H D, Parmar, M, Panico, M B, Pisupati, V, Shichkin, V P, Stacey, A R, Tedesco, F S, Thompson, O & Wagey, R 2019, ' Stem cell culture conditions and stability : A joint workshop of the PluriMes Consortium and Pluripotent Stem Cell Platform ', Regenerative Medicine, vol. 14, no. 3, pp. 243-255 . https://doi.org/10.2217/rme-2019-0001 Regenerative medicine Regenerative Medicine |
| ISSN: | 1746-0751 |
| Popis: | Human stem cells have the potential to transform medicine. However, hurdles remain to ensure that manufacturing processes produce safe and effective products. A thorough understanding of the biological processes occurring during manufacture is fundamental to assuring these qualities and thus, their acceptability to regulators and clinicians. Leaders in both human pluripotent and somatic stem cells, were brought together with experts in clinical translation, bio-manufacturing and regulation, to discuss key issues in assuring appropriate manufacturing conditions for delivery of effective and safe products from these cell types. This report summarizes the key issues discussed and records consensus reached by delegates and emphasizes the need for accurate language and nomenclature in the scientific discourse around stem cells. Lay abstract Novel therapies derived from different kinds of precursor cells and stem cells are increasingly moving to clinical trials to restore tissue function in patients who have suffered injury or disease. The manufacture of these new therapies is unusually complex, which means that the manufacturing processes require great attention to assure they are safe and effective. This paper describes a conversation amongst experts in the field who are exploring therapeutic applications of two different kinds of stem cells (pluripotent stem cells and tissue-derived stem/precursor cells). It considers critical issues in developing the manufacturing process for each of these quite different cells types. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|